BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/27/2022 10:06:45 AM | Browse: 727 | Download: 1683
Publication Name World Journal of Gastroenterology
Manuscript ID 79986
Country China
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Minireviews
Article Title Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease
Manuscript Source Invited Manuscript
All Author List Yi-Han Xu, Wei-Ming Zhu and Zhen Guo
ORCID
Author(s) ORCID Number
Yi-Han Xu http://orcid.org/0000-0002-9138-4614
Wei-Ming Zhu http://orcid.org/0000-0002-8900-1186
Zhen Guo http://orcid.org/0000-0002-1541-421X
Funding Agency and Grant Number
Funding Agency Grant Number
Jiangsu Provincial Health Commission M2021013
Science Foundation of Jinling Hospital YYMS2021035
Corresponding Author Zhen Guo, MD, PhD, Professor, Department of General Surgery, Affiliated Jinling Hospital, Medical School of Nanjing University, No. 305 East Zhongshan Road, Nanjing 210002, Jiangsu Province, China. guozhi0809@sina.com
Key Words Inflammatory bowel diseases; Biologic; Dual targeted therapy; Therapeutic drug monitoring; Bispecific antibodies
Core Tip The emergence of biologics and small molecules has significantly changed the therapies used for inflammatory bowel disease (IBD). However, the efficacy of these drugs is not satisfactory for every patient, which indicates an unmet need for optimizing the use of biologics/small molecules and for predicting therapeutic responses. Here, we describe the current status of novel biologics and small molecules and new treatment strategies to combat IBD by using more than one biologic.
Publish Date 2022-12-27 10:06
Citation Xu YH, Zhu WM, Guo Z. Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease. World J Gastroenterol 2022; 28(48): 6888-6899
URL https://www.wjgnet.com/1007-9327/full/v28/i48/6888.htm
DOI https://dx.doi.org/10.3748/wjg.v28.i48.6888
Full Article (PDF) WJG-28-6888.pdf
Full Article (Word) WJG-28-6888.docx